Vaxcyte Inc.
Rating
Updated: Aug 11, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infecti...
Latest News
7 days ago · defenseworld.net
California State Teachers Retirement System Has $475.89 Million Stake in Vaxcyte, Inc. $PCVXCalifornia State Teachers Retirement System boosted its position in Vaxcyte, Inc. (NASDAQ: PCVX) by 5,915.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,186,622 shares of the company's stock after buying an additional 8,050,522 shares during the quarter. California State Teachers
14 days ago · fool.com
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider FilingAndrew Guggenhime surrendered 2,705 shares at $61.18 per share on August 31 and September 2, representing a transaction value of $165,492. The transaction size represents 2% of the total equity stake held before the filing.
14 days ago · fool.com
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should KnowThe transactions represented a combined value of about $378,000 based on weighted average prices of $61.12 per share. Jim Wassil traded shares equal to 4% of the stake held before the filing.
14 days ago · fool.com
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the FirmThe disposition of 6,289 shares at $61.20 per share represented a transaction value of about $384,900. The transaction involved shares equal to 0.87% of the total equity stake held before the filing, resulting in a minor reduction of the overall position.
19 days ago · globenewswire.com
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline DataLuis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development and Medical Affairs for Pneumococcal Conjugate Vaccines Prevnar 13 and Prevnar 20, Joins Vaxcyte as Chief Medical Officer
26 days ago · globenewswire.com
Vaxcyte to Participate in Upcoming Investor ConferencesSAN CARLOS, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in fireside chats and host one-on-one meetings at the following investor conferences:
1 month ago · 247wallst.com
If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long GoneSeth Klarman's Baupost Group eliminated its entire stake in Vaxcyte (NASDAQ:PCVX | PCVX Price Prediction) during the June quarter, according to the 13F filed August 13, 2026.
2 months ago · defenseworld.net
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of “Hold” from AnalystsShares of Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) have been given an average rating of "Hold" by the nine analysts that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company.
4 months ago · globenewswire.com
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy AdultsFirst-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus
4 months ago · seekingalpha.com
Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptVaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Analyst Summary
Add to Watchlist
Select watchlists to add or remove PCVX